{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:23:07Z","timestamp":1769008987817,"version":"3.49.0"},"reference-count":26,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropediatrics"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Objective\u2003Epilepsy is common among patients with severe motor and intellectual disabilities (SMID) patients, often taking a prolonged and intractable course. Lacosamide (LCM) is widely used to treat epilepsy in both adults and children. We assess the efficacy and tolerability of LCM among pediatric and young adult epilepsy patients with SMID who suffer from intractable seizures.<\/jats:p><jats:p>\n          Methods\u2003This retrospective analysis reviewed the medical records of SMID patients undergoing LCM treatment for more than a year. The study included 24 patients (14 males) aged 3 to 29 years. Epilepsy was classified as focal in 17 patients, generalized in 4 patients, and combined generalized and focal in 3 patients.<\/jats:p><jats:p>\n          Results\u2003The retention rates were 70.8%, 65%, and 52.9% at 1, 2, and 3 years after LCM initiation, respectively. The 50% responder rate (achieving &gt;50% seizure reduction) for LCM treatment was 50%, with two patients experiencing complete seizure control (absence of seizures for 6 months before the follow-up visit). The 50% responders included a higher proportion of patients with focal epilepsy (58.8%) compared to those with generalized epilepsy (25.0%). Treatment-emergent adverse events (TEAEs) included somnolence in five patients and nausea in two patients. TEAEs, particularly nausea, developed within 1 month after treatment initiation in two patients, leading to LCM discontinuation.<\/jats:p><jats:p>\n          Conclusion\u2003LCM demonstrated good efficacy for intractable epilepsy in pediatric and young adult SMID patients. It was generally well-tolerated, resulting in a favorable retention rate. LCM emerged as a useful antiseizure medication for epilepsy treatment in pediatric and young adult SMID patients.<\/jats:p>","DOI":"10.1055\/a-2508-5990","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:39:07Z","timestamp":1735605547000},"page":"119-124","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Tolerability of Lacosamide in Pediatric and Young Adult Epilepsy Patients with Severe Motor and Intellectual Disabilities"],"prefix":"10.1055","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2416-5697","authenticated-orcid":false,"given":"Nobutsune","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hiroshima Prefectural Hospital, Minami-ku, Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hiroshima Prefectural Hospital, Minami-ku, Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Komori","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hiroshima Prefectural Hospital, Minami-ku, Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3907-9863","authenticated-orcid":false,"given":"Hiroki","family":"Izumo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hiroshima Prefectural Hospital, Minami-ku, Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Goda","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hiroshima Prefectural Hospital, Minami-ku, Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayana","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hiroshima Prefectural Hospital, Minami-ku, Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Jinno","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hiroshima Prefectural Hospital, Minami-ku, Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies","volume":"88","author":"K M Fiest","year":"2017","journal-title":"Neurology"},{"key":"ref2","first-page":"264","article-title":"Future perspective in the study of developmental disabilities [in Japanese]","volume":"17","author":"M Arima","year":"1996","journal-title":"Hattatsu Shogai Kenkyu (Tokyo)"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eplepsyres.2007.09.006","article-title":"Epilepsy in severe motor and intellectual disabilities syndrome (SMIDS)\u2013a clinical and electroencephalographic study of epileptic syndromes","volume":"77","author":"A Matsumoto","year":"2007","journal-title":"Epilepsy Res"},{"issue":"07","key":"ref4","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"E Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.yebeh.2011.08.032","article-title":"Add-on lacosamide: a retrospective study on the relationship between serum concentration, dosage, and adverse events","volume":"22","author":"B Hillenbrand","year":"2011","journal-title":"Epilepsy Behav"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.seizure.2017.09.019","article-title":"Safety of intravenous lacosamide in critically ill children","volume":"52","author":"S S Welsh","year":"2017","journal-title":"Seizure"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"100402","DOI":"10.1016\/j.ebr.2020.100402","article-title":"The effect of lacosamide on psychiatric comorbidities in patients with epilepsy","volume":"14","author":"N Hasegawa","year":"2020","journal-title":"Epilepsy Behav Rep"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.seizure.2018.01.014","article-title":"Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: a systematic review","volume":"56","author":"J S Ortiz de la Rosa","year":"2018","journal-title":"Seizure"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"108614","DOI":"10.1016\/j.yebeh.2022.108614","article-title":"Clinical impact of the dose and blood concentration of lacosamide in Japanese pediatric patients with epilepsy: a cohort study","volume":"129","author":"N Ishikawa","year":"2022","journal-title":"Epilepsy Behav"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.seizure.2020.02.013","article-title":"Lacosamide in the general population and in people with intellectual disability: similar responses?","volume":"76","author":"J Allard","year":"2020","journal-title":"Seizure"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejpn.2013.08.006","article-title":"Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy","volume":"18","author":"S Grosso","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11636260-000000000-00000","article-title":"Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: a prospective, open-label, observational, multicenter study in Spain","volume":"12","author":"C Casas-Fern\u00e1ndez","year":"2012","journal-title":"Drugs R D"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1684\/epd.2015.0782","article-title":"Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study","volume":"17","author":"J F Toupin","year":"2015","journal-title":"Epileptic Disord"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"108598","DOI":"10.1016\/j.yebeh.2022.108598","article-title":"Lacosamide effectiveness and tolerability in patients with drug-resistant epilepsy and severe disability under polytherapy: Therapy optimization as emerging from an observational study","volume":"128","author":"M Pozzi","year":"2022","journal-title":"Epilepsy Behav"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s13760-019-01098-3","article-title":"Lacosamide in patients with intellectual disability and refractory epilepsy","volume":"119","author":"A Kleist","year":"2019","journal-title":"Acta Neurol Belg"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2016.12.015","article-title":"Lacosamide for uncontrolled primary generalized tonic-clonic seizures: an open-label pilot study with 59-week extension","volume":"130","author":"R T Wechsler","year":"2017","journal-title":"Epilepsy Res"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1136\/jnnp-2020-323524","article-title":"Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial","volume":"91","author":"D G Vossler","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.seizure.2012.12.009","article-title":"Lacosamide in pediatric and adult patients: comparison of efficacy and safety","volume":"22","author":"A Verrotti","year":"2013","journal-title":"Seizure"},{"issue":"07","key":"ref19","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/0883073816630084","article-title":"Efficacy and tolerability of lacosamide in the treatment of children with refractory generalized epilepsy","volume":"31","author":"C Miskin","year":"2016","journal-title":"J Child Neurol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.seizure.2019.05.016","article-title":"Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures - an open-label trial","volume":"71","author":"J A Ferreira","year":"2019","journal-title":"Seizure"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2011.11.026","article-title":"Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA","volume":"23","author":"V Villanueva","year":"2012","journal-title":"Epilepsy Behav"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/epi.14071","article-title":"Long-term efficacy of add-on lacosamide treatment in children and adolescents with refractory epilepsies: a single-center observational study","volume":"59","author":"A Rosati","year":"2018","journal-title":"Epilepsia"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/epi.13869","article-title":"Lacosamide in the treatment of patients with epilepsy and intellectual disabilities: a long-term study of 136 patients","volume":"58","author":"S B\u00f6ttcher","year":"2017","journal-title":"Epilepsia"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1442-200X.1961.tb01032.x","article-title":"Analytic test for development in infancy and childhood","volume":"4","author":"M Enjoji","year":"1961","journal-title":"Pediatr Int (Roma)"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.anl.2018.12.003","article-title":"Developmental delays assessed using the Enjoji Scale in children with cochlear implants who have intellectual disability with or without autism spectrum disorder","volume":"46","author":"M Motegi","year":"2019","journal-title":"Auris Nasus Larynx"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1440-1819.2009.01931.x","article-title":"Utility of the Kyoto Scale of Psychological Development in cognitive assessment of children with pervasive developmental disorders","volume":"63","author":"T Koyama","year":"2009","journal-title":"Psychiatry Clin Neurosci"}],"container-title":["Neuropediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2508-5990.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T23:41:01Z","timestamp":1741390861000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2508-5990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":26,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2025,3,7]]},"published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2508-5990","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0174-304X","1439-1899"],"issn-type":[{"value":"0174-304X","type":"print"},{"value":"1439-1899","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,30]]},"published":{"date-parts":[[2024,12,30]]}}}